Division of Clinical Pharmacology and Toxicology Service, Geneva University Hospitals, Geneva, Switzerland.
Division of General Internal Medicine, Geneva University Hospitals, Geneva, Switzerland.
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.00274-21.
We sought in this case-control retrospective study to compare posaconazole and isavuconazole (PCZ and IVC, respectively) plasma trough concentration () levels in high-risk allogeneic hematopoietic cell transplant (HCT) recipients who received letermovir (LET) or not. PCZ/IVC levels were not found to be significantly different between cases and controls, as they were 1.31 mg/liter (median) (interquartile range [IQR], 0.90) versus 1.36 mg/liter (IQR, 1.16) ( = 0.31) and 3.20 mg/liter (IQR, 2.40) versus 2.35 mg/liter (IQR, 1.50) ( = 0.17), respectively. In conclusion, we observed PCZ/IVC levels within the expected range and no significant effect of LET coadministration.
我们在这项回顾性病例对照研究中比较了接受来特莫韦（LET）或未接受 LET 的高危异基因造血细胞移植（HCT）受者的泊沙康唑和伊曲康唑（PCZ 和 IVC）血药谷浓度（）水平。病例组和对照组之间的 PCZ/IVC 水平没有显著差异，分别为 1.31mg/L（中位数）（四分位距 [IQR]，0.90）与 1.36mg/L（IQR，1.16）（=0.31）和 3.20mg/L（IQR，2.40）与 2.35mg/L（IQR，1.50）（=0.17）。总之，我们观察到 PCZ/IVC 水平在预期范围内，且 LET 联合用药无显著影响。
